Breakthrough Immunotherapy Backfires Resulting in Fatal Relapse

Oct 3, 2018 | CAR-T, Oncology, Patient Safety, Site Challenges, Site Watch

As reported in the New York Times by Denise Grady, covering news of work with CAR-T gene therapy reports that “a highly unusual death has exposed a weak spot in the groundbreaking cancer treatment: One rogue cell, genetically altered by the therapy, can spiral out of control in a patient and cause a fatal relapse. In this case the biological engineering actually “helped a cancer cell elude detection, triggering a fatal relapse.” Read Ms. Grady’s story for the full details.


Pin It on Pinterest